ロード中...
Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations
Down syndrome (DS), also known as trisomy 21, is the most common genetic cause of intellectual disability (ID). Although ID can be mild, the average intelligence quotient is in the range of 40–50. All individuals with DS will also develop the neuropathology of Alzheimer’s disease (AD) by the age of...
保存先:
| 出版年: | Drug Des Devel Ther |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2014
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4277121/ https://ncbi.nlm.nih.gov/pubmed/25552901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S51476 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|